A Phase I/II Study of BMS-247550 [ixabepilone] and Pegylated Liposomal Doxorubicin (Doxil) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane and Phase I Study of Patients With Metastatic Breast Cancer

Trial Profile

A Phase I/II Study of BMS-247550 [ixabepilone] and Pegylated Liposomal Doxorubicin (Doxil) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane and Phase I Study of Patients With Metastatic Breast Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Ixabepilone (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Mar 2016 A protocol amendment was made during phase I trial from a treatment regimen of Schedule A (ixabepilone every 3-4 weeks) to Schedule B (ixabepilone every week). The maximum tolerated dose was determined to be the preceding dose of any dose that resulted in 2 DLT events. Schedule B was carried forward to the phase II trial. The Maximum Tolerated Dose for Schedule B is reported.
    • 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top